Bimodal Therapeutic Agents against Glioblastoma, one of the most Lethal Cancer release_rev_325ada5e-9fb7-4b7d-a460-a3cfa242d7ae

by Hugo Eduardo Cerecetto, Marcos Couto, Catalina Alamón, Susana Nievas, María Alejandra Dagrosa, Francesc Teixidor, Pablo Cabral, Clara Viñas, Marina Perona

Published in Chemistry - A European Journal by Wiley.

2020  

Abstract

About 95% of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two-in-one hybrid systems should be implemented. Tyrosine kinase receptors-inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated-carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral- and BNCT-agents. One of the selected hybrids was studied against glioma-cells finding that it was 4-times more cytotoxic than sunitinib and 1.7-times more effective than 10B- boronophenylalanine fructose complex when the cells were irradiated with neutrons.
In text/plain format

Type  article-journal
Stage   published
Date   2020-08-01
Language   en ?
Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  0947-6539
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Revision

This is a specific, static metadata record, not necessarily linked to any current entity in the catalog.

Catalog Record
Revision: 325ada5e-9fb7-4b7d-a460-a3cfa242d7ae
API URL: JSON